Payers Must Cover HIV Prevention Drugs Without Cost-Sharing in Two Months

Federal regulations will require payers to cover HIV prevention drugs and care. Gilead’s HIV drug Truvada has faced criticism due to its high monthly cost of $2,000, with generics priced at $6 per month.

“Insurers were already required to quit charging out-of-pocket fees for the drugs, called HIV Preexposure Prophylaxis (PrEP), by January of this year. But now insurers have 60 days to comply with the additional requirements, including no-cost services like baseline and follow-up testing, as well as monitoring, according to the guidance.” Read more here.

(Source: Nicole DeFeudis, Endpoints News, 7/21/21)